HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
However, some formulations contain additional ingredients that may be comedogenic for sensitive individuals
How do I know if I actually need the KLOW peptide blend
Both BMAC and MFAT deliver similar results, although BMAC is generally used for younger, bone-involved OA, while MFAT is considered a better fit for elderly patients and those with higher body weight